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Borna disease is a chronic neurological disease caused by an enveloped negative-strand RNA virus (BDV). Experimental 
disease can be reproduced in rats with brain homogenates derived from infected animals or with virus derived from infected 
cells in culture. The virus replicates in cultured cells without evidence of cytopathic effect or production of significant levels 
of cell-free virus. Borna disease is caused by an immunopathological response to viral infection of neural cells, To further 
investigate the pathogenesis of Borna disease, rats were inoculated with different doses of BDV attenuated by culture in 
MDCK cells, Low doses of attenuated BDV (102-104 TCIDs0) resulted in typical clini(}al disease and severe encephalitis; 
however, the lag period between inoculation and disease was considerably longer than that with virulent BDV. In contrast, 
animals inoculated with a high close of attenuated BDV (105-10 e TCIDao) did not develop clinical disease, although a mild 
encephalitic response was present that did not progress beyond the mild encephalitis. Animals inoculated with a high dose 
of BDV developed high titers of anti-BDV antibody and were protected against virulent challenge. Protection was correlated 
with the rapid induction of an immune response in the animals and the lack of any biologically detectable virus in the CNS. 
© 1995 Academic Press, Inc, 
INTRODUCTION 
Borna disease (BD) is a chronic encephalitis of horses 
and sheep (Heinig, 1969) that is caused by an enveloped 
negative-strand RNA virus (BDV) (VandeWoude et aL, 
1990; Lipkin et aL, 1990; Briese et al., 1992; Richt et aL, 
1991, 1992, 1993; de la Torre etaL, 1990; McOlure etaL, 
1992; Thierer et aL, 1992; Pyper et aL, 1993; Cubitt et al., 
1994; Briese et aL, 1994). Animals with active BD have 
high levels of infectious virus in the brain. Experimentally 
the disease can be reproduced by inoculation of various 
species of animals with brain homogenate from infected 
horses (Narayan et al., 1983a,b). The virus is propagated 
in brain by intracerebral (IC) inoculation of rats (Narayan 
et al., 1983b) or by inoculation of fetal brain cell cultures 
(Herzog and Rott, 1980). Nonneural cells such as MDCK 
cells can be infected by cocultivation with infected fetal 
rabbit brain cells. The MDCK cells become persistently 
infected and do not develop cytopathic effect. Virus ob- 
tained from lysed MDCK cells has attenuated pathoge- 
nicity in rats. 
In weanling rats BDV replicates only in cells in the 
nervous system (Herzog et aL, 1984). inoculation of virus 
intravenously fails to cause infection, and the virus is 
cleared rapidly from circulation (Carbone et aL, 1987). 
~To whom correspondence and reprint requests should be ad- 
dressed. 
However, when inoculated intranasally (Morales et aL, 
1988) or in the footpad (Carbone eta/., 1987) BDV enters 
peripheral nerves and is transported within neuronal pro- 
cesses to ganglia and the brain where replication occurs. 
The virus replicates preferentially in neurons of the limbic 
system of the brain and the rate of replication is a func- 
tion of the dose of virus in the inoculum (Carbone et 
aL, 1987). In addition to neurons, astrocytes are also 
frequently infected, particularly after the acute phase of 
disease (Carbone et aL, 1989, 1991). Rats inoculated IC 
with undiluted infectious brain homogenate (containing 
104 TCIDso) have detectable virus by Day 6, whereas 
those inoculated with low doses (10 TCIDso) require 3 to 
4 weeks for detectable virus replication. In both cases, 
once begun, virus replication continues exponentially to 
high titers in the brain (106 TOID~o/ml of 10% brain homog- 
enate). Replication of BDV in the CNS elicits a severe 
inflammatory response characterized by an influx of 
CD4+ and CD8+ T-lymphocytes, B-lymphocytes, and 
macrophages (Deschl et aL, 1990), frequently accompa- 
nied by loss of infected brain cells. Encephalitis becomes 
apparent at the time of exponential virus replication, be- 
ginning about 14 days following inoculation with 104 
TCIDs0 of brain homogenate and 4-6 weeks following 
10 TOIDs0 (Carbone et aL, 1987)-. Animals surviving acute 
BDV encephalitis have extensive atrophy of the cerebral 
cortex and a reduced virus burden in the brain (Carbone 
et aL, 1987). Lesions and disease are preventable by 
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treatment of infected animals with drugs or antisera that 
prevent inflammation (Narayan et al., 1983b; Stitz et al., 
1989, 1992); these treatments are effective only if admin- 
istered no later than 1 day after virus inoculation. In- 
fected, treated animals become virus carriers, supporting 
extensive replication in the brain. These animals readily 
develop disease after adoptive immunization with BDV- 
specific T-cells (Narayan et aL, 1983b; Richt et aL, 1989). 
Thus, the inflammatory disease is caused by the cell- 
mediated immune response to the virus and this is de- 
pendent on expression of viral antigens in CNS cells 
during exponential virus replication in the brain. 
In this study, cell-culture-attenuated BDV was exam- 
ined in weanling rats for its potential to cause disease 
and to generate immune responses in infected animals. 
Inoculation of low doses paralleled virulent virus infec- 
tion although pathological changes, virus replication, and 
the immune response were delayed for a month. It was 
found that inoculation of a high dose of attenuated BDV 
resulted in a rapid, vigorous immune response without 
virus replication. The animals were protected against 
challenge with virulent BDV. 
Histopathology and Immunohistochemistry 
Brain tissue was fixed in 10% buffered formalin and 
embedded in paraffin. Routine hematoxylin and eosin 
staining was performed on 5-#m sections. Four sagittal 
sections of the brain were examined on each rat. Patho- 
logical changes were graded as mild (occasional peri- 
vascular cuffs and only mild cortical hypercellularity), 
moderate (numerous perivascular cuffs, cortical hyper- 
cellularity, and diffuse parenchymal inflammation espe- 
cially in cerebral cortex and hippocampus), or severe 
(large number of perivascular cuffs, severe diffuse corti- 
cal and hippocampal inflammation, and neuronal degen- 
eration and loss). An avidin-biotin-peroxidase method 
(Vector Laboratories, Burlingame, CA) was used with the 
Bo18 menoclonal antibody (Haas et aL, 1986) to detect 
BDV-infected cells and with anti-GFAP (DAKO) to detect 
astrocytes. Lectin histochemistry using the biotinylated 
lectin Ricinus communis  agglutinin-I (RCA-I) (Vector) was 
used to identify macrophages as described ($harma et 
al., 1992). 
Measurement of virus titers in brain 
MATERIALS AND METHODS 
Virus 
Persistently BDV-infected Madin Darby canine kidney 
(BDV/MDCK) cells were used as a source of virus (Her- 
zog and Rot[, 1980). To obtain stock virus, confluent 
monolayers of BDV/MDCK were prepared by cultivation 
of the cells in MEM with 10% FBS. Approximately 109 
cells were suspended in 20 ml of MEM plus 5% FBS and 
sonicated for 30 sec at 4 °. This stock virus was stored 
in aliquots at -70 ° and had a titer of 5 x 107 TCIDso/ml. 
Virus stocks were assayed for infectivity in fetal rabbit 
glial cultures prepared from brains of 16-day-old fetal 
rabbits and stored in liquid nitrogen (Herzog and Rott, 
1980). The glial cells were cultivated in MEM plus 10% 
FBS in chamber slides, inoculated with dilutions of test 
material, and maintained for 7-10 days at 37 ° . The cul- 
tures were then fixed in acetone at 4 ° and BDV antigens 
were detected using an immunofluorescence assay (IFA) 
(Herzog and Rott, 1980). Sera from BDV-infected rats or 
Bo18, a monoclonal antibody to the BDV 38-kDa protein 
(Haas et al., 1986), were used for the IFAs. 
Rats 
Four-week-old outbred CD rats (Charles River) were 
used throughout these experiments. The animals were 
lightly anesthetized with methoxyfluorane and inoculated 
IO with 50 #1 virus material using a 23-gauge needle. 
The animals were killed at various times after inoculation 
by an overdose of methoxyfluorane followed by exsangui- 
nation. 
A 10% rat brain homogenate was prepared in MEM- 
5% FBS using a Dounce homogenizer. Dilutions of the 
homogenate were used to infect fetal rabbit glial cells in 
chamber slides. After incubation for 7-10 days, the cells 
were fixed, and BDV antigens were detected using IFA 
(Herzog and Rott, 1980). 
Measurement of anti-BDV antibody titers in infected 
rats 
Persistently infected MDCK cells were grown on Tef- 
lon-coated slides. Antibody titers were measured in IFAs 
using 10-fold dilutions of sera from infected animals and 
determining the greatest dilution at which the infected 
MDCK cells could be detected. 
In situ hybridization 
Formalin-fixed, paraffin-embedded tissue sections 
were deparaffinized in a graded alcohol series and pre- 
treated with 0.2 N HCI and 25 #g/ml proteinase K. The 
tissues were then acetylated, dehydrated through a 
graded alcohol series, and air-dried as previously de- 
scribed (Zink et al., 1990). In situ hybridization was per- 
formed using the 700-bp cDNA clone B8 (Vande Woude 
et aL, 1990) of BDV that .was radiolabeled by random 
priming using 35S-labeled dCTP (Amersham Corp., Arling- 
ton Heights, IL). B8 is a cDNA clone that encodes the 
24-kDa protein. Radiolabeled DNA (0.2 #g/ml) was dena- 
tured by heating and placed over the pretreated tissues, 
After hybridization (16 hr at RT), the slides were washed, 
dehydrated, dipped in NTB3 autoradiographic emulsion 
(Eastman Kodak Co., Rochester, NY), air-dried, and devel- 
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TABLE 1 
TEMPORAL ANALYSIS OF RATS INFECTED WITH LOw-DOSE (10 z TCIDso) AND HIGH-DOSE (106 TCID~o) ATTENUATED BDV a 
Days No. of rats Virus titer b Viral antigen ° Viral RNA ~ Ab titer e Pathology r
Low dose 
High dose 
17-20 4 0 N.D. N.D. L 
30-40 2 104 ÷ + L 
44-47 1 103 + + + L 
1 104 ++ + L 
2 105 ÷+ + L 
1 106 ÷+ + L 
53 1 104 + + + H 
1 104 ++ + L 
1 106 ++ + H 
1 10 6 ++ + L 
63 2 105 + + L 
68 3 105 ÷+ + H 
2 105 ++ + L 
1 103 ++ + H 
7 1 0 + - L 
11 1 0 + - H 
17 3 0 - - H 
44 2 0 - - H 
53 3 0 - - H 
68 3 0 - - L 















a Rats were inoculated IC with low-dose (102 TCIDso) or high-dose (106 TCIDso) attenuated BDV. At various times after infection they were sacrificed 
for determination of viral titer, presence of viral antigen and RNA in the brain, antibody titer, and pathology. 
b Fetal rabbit glial cells in chamber slides were infected with dilutions of brain homogenate from infected rats. After 7-10 days infected cells 
were identified by IFA. 
c Viral antigen was detected in brain sections by immunohistochemical techniques. -I-, antigen was detected; - ,  antigen was not detected; ND, 
not determined. 
~Viral RNA was detected in brain sections by in situ hybridization using a BDV-specific probe. +, BDV RNA was detected; - ,  BDV RNA was not 
detected. 
e Anti-BDV antibody titers were determined by IFA using dilutions of sera from infected rats and persistently infected MDCK cells that are uniformly 
infected. L, ~<1=100; H, ~1=1000. 
f - ,  no or minimal inflammation; +, mild inflammation; +++,  severe inflammation. 
oped  after  3 to 10 days  exposure  in the dark. S l ides  were  
examined by l ight mic roscopy;  the  presence  of v iral  RNA 
was  ind icated  by s i lver  gra ins  over  cel ls.  
Ana lys i s  o f  BD v i ra l  RNA 
Extraction of RNA. Tota l  RNA was  prepared  f rom rat 
bra ins  us ing the method  of Chomczynsk i  and Sacchi  
(1987). 
Northern analysis. Ten micrograms of tota l  RNA was  
e lec t rophoresed  in a 1% agarose- fo rmaldehyde gel  and 
t rans fer red  to Hybond-N ny lon membrane  (Amersham) .  
After  uv -c ross l ink ing ,  the membrane  was  prehybr id i zed  
at 42 ° in hybr id i za t ion  buffer  conta in ing  50% de ion ized  
fo rmamide ,  6X  SSC, 20 #g/ml  tRNA, 0.05 M HEPES (pH 
7.0), 5X  Denhardt 's ,  1% SDS, 100 #g/ml  hepar in ,  1% gly- 
cine, and 20 #g/ml  son icated  denatured  sa lmon sperm 
DNA. The membrane  was  then  hybr id i zed  at 42 ° w i th  2.5 
X 106 cpm/ml  of a2P-end- labe led o l igonuc leot ide  247 (5'- 
G C CTC CTGACTAATTCAAG CAATGTCAG COG GAG GTC- 
GGAACTC-3 ' ) .  O l igonuc leot ide  247 is an ant i sense  oli- 
gonuc leot ide  der ived  f rom the sequence  encod ing  the 
24-kDa protein.  Af ter  overn ight  hybr id izat ion, ,  the mem-  
brane  was  washed tw ice  at 42 ° w i th  6X  SSC and then  
autorad iographed.  
Semiquantitative RT-PCR. To detect  rare spec ies  of 
RNA, a sens i t ive  RT-PCR techn ique  was  used in wh ich  a 
labe led  o l igonuc leot ide  was  used in the PCR react ion for 
enhanced detect ion  (Saltarel l i  et al., 1993). For reverse 
t ranscr ipt ion,  2.5 #g total  RNA was  denatured  at 68 ° for 
10 min and p laced  on ice. The  react ion conta ined  1 x PCR 
react ion buffer (10 mM Tr i s -HC I  (pH 8.3), 50 mM KCI, 1.5 
mM MgCI2, 0.01% gelat in),  125 #M dATP, 125 #M dCTP, 
125 #M dGTP, 125 #M dq-FP, 100 uni ts /ml  RNasin (Pro- 
mega),  100 uni ts /ml  AMV reverse  t ranscr ip tase  (Life Sci- 
ences),  and 50 #g/ml  pd(N)6 (Pharmac ia)  in a vo lume of 
50 #1. Samples  were  incubated  at 45 ° for 2 hr. Two BDV- 
speci f ic  o l igonuc leot ides  der ived f rom the sequence  en- 
cod ing  the 24-kDa prote in were  used as pr imers  for PCR. 
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Fie. 1. Sections of brain tissue (hippocampus) from rats inoculated with 103 (a) or 106 (b) TCIDso BDV. Brain tissue from animals inoculated with 
the lower dose (a) had severe encephalitis, with marked diffuse and perivascular (arrows) infiltrates of lymphocytes. In contrast, the animals 
inoculated with the higher dose of virus (b) had only mild encephalitis with a minimal increase in the number of cells in the neuropil and rare 
perivascular cuffs. (H&E X100.) 
Oligonucleotide 313 (5'-GCTAGTCGACCCGTCGTAGTG- 
TCTGGGGATC-3') was end-labeled with [-y-32p]ATP and 
T4 polynucleotide kinase. Oligonucleotide 312 (5'-TAC- 
TGOTCGAGCCAAATGCGGCAAACCCCCCG-3') was un- 
labeled. The PCR reaction contained l x PCR buffer, 125 
#M dATP, 125 #M dCTP, 125 ffM dGTP, 125 #M dTTP, 
0.25 nmol/ml of each oligonucleotide and 10 units/ml of 
Taq polymerase (Boehringer-Mannheim) and 50% by vol- 
ume the product of the reverse transcriptase reaction. The 
reaction proceeded for 20 cycles consisting of denatur- 
ation at 94 ° for 1 min, annealing at 55 ° for 1 min, and 
extension for 2 min at 72 °. The 168-nt reaction products 
were resolved by electrophoresing 5-#1 aliquots from the. 
reactions on a 6% polyacrylamide-50% urea denaturing 
gel and were visualized by autoradiography. Control PCR 
reactions contained clone P4 DNA (Vande Woude et aL, 
1990)• P4 contains the BDV sequence from B8 subcloned 
into pGEM 3Z. 
RESULTS 
Kinetics of high and low-dose-attenuated BDV 
infection in rats 
Virulent brain-derived BDV causes an immunopatho- 
logically mediated acute encephalitis and clinical dis- 
ease. Antibodies are produced in response to the infec- 
tion, but high titers are achieved only after the virus has 
already replicated to maximal levels in neural tissues• 
Preliminary experiments were undertaken to examine the 
pathogenesis of tissue culture-attenuated BDV in wean- 
ling rats. Inoculation of attenuated BDV over a range of 
virus doses (102-106 TCIDso) indicated that high doses 
(105 and 106 TCIDso) resulted in the rapid production of 
antiviral antibodies, no detectable virus replication, and 
mild, nonprogressive encephalitis. In contrast, inocula- 
tion with attenuated BDV at low doses (102-104 TCIDso) 
resulted in a delay in the antibody response, productive 
replication of virus in the brain, and progressive encepha- 
litis• The virological, clinical, and pathological aspects of 
the disease were delayed (30 days) in the rats inoculated 
with attenuated low-dose BDV compared to rats inocu- 
lated with virulent BDV (Carbone et aL, 1987). 
To further investigate the kinetics of Borna disease in 
rats infected with attenuated BDV, a longitudinal study 
was undertaken in weanling rats to examine virus repli- 
cation, immune responses, and the development of 
pathological lesions• Fourteen rats were inoculated with 
102 TCID~o and 23 with 10 ~ TCIDso of attenuated BDV. 
Rats from each of the two groups were examined at 
different time points after inoculation, as indicated in Ta- 
ble 1. Animals were examined daily for evidence of clini- 
cal disease. After sacrifice, the brain of each animal was 
divided in half; one half was used for virus titration and 
RNA isolation and the other half was fixed in formalin for 
histology, in situ hybridization, and immunohistochemis- 
try. Blood was collected from all animals for determina- 
tion of antibody levels. 
The brains of the low-dose animals were negative for 
histopathological changes until Day 20 (Table 1), but after 
Day 30, most animals had developed infectivity titers of 
104 to 106 TCIDso/ml. These animals had not produced 
detectable antibodies or inflammatory cell infiltrates to 
BDV by 47 days p.i., despite large amounts of virus in 
the brain. After this time, several of these low-dose-inocu- 
lated animals developed clinical disease and many had 
severe pathological lesions (Fig. la). Viral RNA and anti- 
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FIG. 2. Sections of brain tissue (hippocampus) from rats inoculated with 103 (a, c) or 106 (b, d) TCIDso BDV and stained for vRNA by in situ 
hybridization (a, b) or for viral antigen by immunohistochemistry (c, d). The animals inoculated with the lower dose of virus had abundant viral RNA 
and antigen (arrows), whereas those inoculated with the higher dose of BDV had no evidence of viral RNA or antigen. 
gen were present in large amounts in neurons and 
astrocytes in the cerebral hemispheres, especially in the 
hippocampus (Figs. 2a and 2c) and the frontal cortex 
of the brain. Lectin histochemical stains of brain tissue 
demonstrated abundant activated macrophages in the 
brain (Fig. 3a). There were also numerous activated 
astrocytes as determined by immunohistochemical stain- 
ing of brain tissue with antibodies to glial fibrillary acidic 
protein (Fig. 3c). Northern blot analysis of RNA extracted 
from brain confirmed high levels of viral mRNA (Fig. 4). 
None of the animals inoculated with high doses of 
attenuated virus had become ill by Day 68. Beyond Day 
44 a few of the animals had mild encephalitis (Fig. l b; 
Table 1), but most had no histological changes in the 
brain. No virus could be cultured from the brains of any 
of these animals (Table 1). Examination of tissues from 
these animals by in situ hybridization and immunocyto- 
chemistry showed no viral RNA or antigen (Figs. 2b and 
2d). In contrast, BDV-specific antibodies were present in 
serum of high-dose-inoculated rats from Day 7 onward. 
Antibody titers greater than 1,1000 were detectable by 
Day 11 after infection. These high dose-inoculated ani- 
mals had minimal macrophage infiltrates and minimal 
increases in glial fibrillary acidic protein expression in 
astrocytes when compared to the animals inoculated 
with the low dose of virus (Figs. 3b and 3d). Thus, animals 
inoculated with a high dose of BDV had minimal changes 
in the brain by a number of parameters. 
Northern analysis of RNA extracted from brain of high- 
dose-inoculated animals and hybridized with BDV-spe- 
cific probes was negative (data not shown). A more sen- 
sitive assay of BDV RNA using reverse transcription/PCR 
analysis of RNA isolated from brain showed very low but 
detectable levels of viral RNA (Fig. 5). This level of RNA 
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FJG, 3. Sections of hippocampus from rats inoculated with 103 (a, c) or 106 (b, d) TCIDso BDV and stained histochemically using the lectin RCA- 
1 that identifies brain macrophages (a, b) and GFAP that detects astrocytes (c, d), Tissue from animals inoculated with the low-dose virus showed 
an influx of activated macrophages (arrows) in the neuronal layer and abundant activated astrocytes (arrowheads) in contrast to animals inoculated 
with the high dose of virus. (Hematoxylin ×400.) 
was estimated to be 10,000-fold less than that found in 
brains of animals with clinical BD. 
Despite the lack of infectious virus and the extremely 
low levels of viral RNA in the brain of the high-dose ani- 
mals, inoculation of rats with 10% homogenate of brain 
(obtained from 12 high dose rats 47 days postinoculation) 
resulted in classical BD with severe encephalitis, indicat- 
ing the presence of virulent virus in the brain homogenate. 
High titers of virus, viral RNA, and viral proteins were 
easily detected in brains of these recipient animals (data 
not shown). This provides intriguing data that low levels 
of BDV persisted in the brain of these rats. 
Low-dose BDV/MDCK challenge of passively 
immunized rats 
The observation that animals inoculated with a high 
dose of attenuated virus rapidly developed high anti-BDV 
antibody levels and did not develop disease suggested 
that the presence of antibody.early in the infection might 
be protective. Although earlier studies failed to show a 
protective effect of antisera (Carbone et aL, 1987; Nara- 
yan et al., 1983b), we tested this concept again by pas- 
sively immunizing rats with sera obtained from high dose 
animals (anti-BDV antibody titers >1=1000) and challeng- 
ing with low-dose BDV/MDCK virus. Four rats were inoc- 
ulated intraperitoneally with antiserum 1 day prior to and 
on the day of virus challenge, and the antibody treat- 
ments were repeated on Days 7, 14, and 21 postinocula- 
tion. These four animals and four control rats were inocu- 
lated IC with 102 TCID~o of attenuated BDV. On Day 7 
postinfeetion, all rats had BDV antibody titers ranging 
from 1=10 to 1=100. The experiment was terminated on 
Day 50 and brains were examined for encephalitis and 
virus load. All four control animals and three of the four 
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FIG. 4. Northern analysis of RNA from rats infected with low-dose 
infectious BDV-MDCK. Rats were inoculated with 10 ~ TCIDso of BDV- 
MDCK and sacrificed at various times postinfection for analysis of BDV 
RNA species in their brains. RNA (10 #g) was used for each sample. 
After electrophoresis in an agarose-formaldehyde gel and transfer to 
a Hybond-N nylon membrane (Amersham), BDV RNA species were 
detected by hybridization using an oligenucleotide probe (247) that 
detects BDV positive-strand RNAs. This probe shows some cross-reac- 
tion with 28S ribosomal RNA as can be seen in lane 2 (uninfected rat 
brain RNA), especially after the long exposure used here to enhance 
detection of BDV RNA species at early time points. Lanes, M, marker 
lane containing the end-labeled 1-kb DNA ladder (Life Sciences); 1, 
RNA from rat brain infected with nonattenuated rat brain-passaged 
BDV; 2, RNAfrom uninfected rat brain. Lanes 3 9 contain RNAfrom 
the brains of BDV-MDCK animals sacrificed at different times after 
infection= 3, 40 days p.i.; 4, 30 days p.i.; 5, 30 days p.i.; 6, 40 days p.i.; 
7, 44 days p.i.; 8, 53 days pJ.; 9, 53 days p.i. 
animals receiving passive immunization had equivalent 
amounts of virus in the brain. Encephalitic lesions were 
indistinguishable between the test and control groups 
(data net shown). Thus, passive immunization with sera 
failed to protect animals against virus replication or the 
development of lesions in the brain. 
Virulent BDV challenge of rats previously inoculated 
with high- or low-dose BDV/MDCK virus 
Since animals inoculated with high-dose-attenuated 
BDV had only minimal infectious virus in the brain, we 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
FIG. 5. Semiquantitative RT-PCR of RNA from rats infected with high- 
dose infectious BDV-MDCK. Rats were inoculated with 106 TCID~0 of 
BDV-MDCK and sacrificed at various times after infection for analysis 
of BDV RNA species present in their brains. Lanes 1-6 contain PCR 
products from animals infected with BDV-MDCK and sacrificed at differ- 
ent times postinfection= Iane 1, 7 days p.i.; lane 2, 11 days p.i.; lane 3, 
44 days p.i.; lane 4, 53 days p.i.; lane 5, 68 days p.i.; lane 6, 68 days 
p.i.; lane 7, no RNA; lane 8, RNA from uninfected rat brain. Lanes 9 
12 contain RNA from rat brain infected with nonattenuated rat brain 
passaged BDV which has been serially diluted with RNA from unin- 
fected rat brain. The dilutions used were= lane 9, 104 dilution; lane 10, 
103 dilution; lane 11, 102 dilution; lane 12, 10-fold dilution. Lanes 13 
and 14, control PCR reactions containing 5 pg(lane 13) and 1 pg (lane 
14) of clone P4 DNA. 
TABLE 2 
RAT BRAIN VIRUS CHALLENGE 30 DAYS AFTER INOCULATION WITH LOW- 
OR HIGH-DOsE-ATTENUATED BDV a 
Test No. of Clinical Virus in 
regimen rats disease Pathology b brain 
High dose 5 0/5 N 0/5 
Low dose 4 2/4 ++4-  4/4 
Control 2 2/2 4- + + 2/2 
a Rats were inoculated IC with a high (106 TCID~0) or low (102 TCID66) 
dose of atten~uated BOV, followed 30 days later by challenge with 104 
TCID66 of virulent rat brain virus. They were monitored for the develop- 
ment ef clinical disease and sacrificed after 23 days. 
Severity of lesions, N, none or mild inflammation; +++,  severe 
inflammation. 
next determined whether such animals could be chal- 
lenged with virQlent rat brain BDV. Five rats were inocu- 
lated with 106 TCID~o of attenuated BDV, four with 102 
TCID~o-attenuated BDV, and two were sham inoculated. 
All 11 rats were challenged IC with 50 #1 of undiluted rat 
brain virus (104 TCID~o) 30 days later. The control animals 
and two of the four animals inoculated with low doses 
of the attenuated virus developed clinical Borna disease 
during the following 3 weeks (Table 2). Both controls and 
all four low-dose animals had severe encephalitis. In 
striking contrast, the five animals that received high 
doses of the attenuated BDV remained completely refrac- 
tory to challenge with the virulent virus when examined 
23 days later. No trace of viral RNA or antigen was detect- 
able by in situ hybridization or immunocytochemistry and 
no infectious virus was recovered from the brains of 
these animals, as assayed by inoculation of fetal rabbit 
glial cultures. Mild encephalitis, markedly less dramatic 
than that seen in the other two groups was, however, 
present in all five of the high-dose-inoculated animals. 
This pathologic response was indistinguishable from that 
seen in other animals that had received the high-dose 
virus. 
DISCUSSION 
In this study, intracerebral inoculation of rats with a 
high dose of tissue culture-attenuated BDV resulted in 
a rapid and vigorous anti-BDV antibody response with 
minimal virus replication in the brain and without the 
development of the immunopathologic lesions typical of 
Borna disease. Virus persisted in the brains of inoculated 
rats for at least 10 weeks without evidence of replication. 
When these animals were challenged with highly virulent 
virus from rat brain homogenate, they neither became 
infected nor showed signs of disease. Resistance to 
challenge was measured in terms of restriction of virus 
replication, failure to develop progressive lesions, and 
failure to develop clinical Borna disease. This lack of 
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virus replication and the resistance to virulent virus chal- 
lenge correlated with the rapid and vigorous antibody 
response. 
Our hypothesis is that these animals mounted a strong 
and rapid immune response to the high dose BDV. The 
rapid development of antibodies to BDV probably reflects 
the early response of both the cellular and humoral com- 
ponents of the immune system. The induction of an early 
strong cell-mediated immune (CMI) response before viral 
replication had progressed to exponential phase may 
have aborted further virus replication. These animals 
maintained high levels of antibodies, but minimal viral 
antigen was available to attract potentially immunopatho- 
logic cells to the brain and thus there was no clinical 
disease and only minimal pathological changes. In the 
case of the low-dose animals, the immune response was 
delayed, and virus replication proceeded leading to pro- 
duction of the immune response, in this case the destruc- 
tion of infected cells resulted in the severe pathology 
typical in BD. The resistance of the high dose rats to 
challenge with virulent rat brain virus demonstrates that 
the protective immune response had been established 
bythe high-dose infection, and not bythe low-dose infec- 
tion. The immune systems of the high-dose animals were 
able to rapidly respond to the challenge dose before 
the virus infected many cells, in contrast, the low-dose 
animals rapidly succumbed to the virulent virus, sug- 
gesting the immune response was unable to protect 
against challenge. 
Earlier studies on BDV pathogenesis had showed that 
the development of lesions came on the heels of produc- 
tive virus replication in brain, irrespective of the length of 
time the virus required to go into exponential replication. 
Additional studies supported this paradigm of sequential 
progression of Borna disease which starts with viral repli- 
cation followed by CMI responses and then pathological 
changes. In these experiments, lesions in the brain and 
clinical disease developed in immunosuppressed ani- 
mals within a few days following adoptive transfer of 
virus-specific immune cells (Narayan, et al., 1983b). 
The rapid decline in virus burden in the brain of high- 
dose-inoculated rats may be due to elimination of the 
few cells actively replicating virus by the putative CMI 
response in these animals. A similar decline in virus 
burden had been observed in animals surviving the nec- 
rotizing encephalitic process caused by infection with rat 
brain-derived virus (Carbone et aL, 1987). The extensive 
loss of neurepil in these animals is compatible with elimi- 
nation of infected cells from the brain. 
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